Clinical Trial Update: Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of temsirolimus and AZD6244 (selumetinib) in treatment-naive patients with BRAF-mutant unresectable Stage IV melanoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Mucosal Melanoma

Drugs mentioned

• Selumetinib (selumetinib)
• Torisel (Temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Mucosal Melanoma, Recurrent Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2013-05-23